Case number 1:23-cv-00625
Array BioPharma Inc. v. Teva Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 22, 2025 | 21 | NOTICE of Withdrawal of Counsel by Array BioPharma Inc. (Dellinger, Megan) (Entered: 05/22/2025) (2) |
| Dec 2, 2024 | 20 | REPLY BRIEF re 17 MOTION to Stay filed by Teva Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(DiBenedetto, Emily) (Entered: 12/02/2024) (0) |
| Nov 22, 2024 | 19 | ANSWERING BRIEF in Opposition re 17 MOTION to Stay - filed by Array BioPharma Inc..Reply Brief due date per Local Rules is 12/2/2024. (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 11/22/2024) (0) |
| Nov 8, 2024 | 17 | MOTION to Stay - filed by Teva Pharmaceuticals, Inc.. (Attachments: # 1 Text of Proposed Order)(DiBenedetto, Emily) (Entered: 11/08/2024) (0) |
| Nov 8, 2024 | 18 | OPENING BRIEF in Support re 17 MOTION to Stay filed by Teva Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 11/22/2024. (DiBenedetto, Emily) (Entered: 11/08/2024) (10) |
| Oct 22, 2024 | 16 | ORAL ORDER: Having reviewed the parties' joint letter (D.I. 15) and given the Court's prior construction of the claim term "crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide" (i.e. "crystallized [binimetinib]") contained in U.S. Patent Nos. 9,562,016 ("the 016 Patent"), 9,598,376 ("the 376 Patent"), and 9,980,944 ("the 944 Patent") (collectively, the "Crystallized Binimetinib Patents") in Array's related litigation against Alembic Pharmaceuticals Limited and Sandoz Inc., Civil Action No. 22-1277-GBW, IT IS HEREBY ORDERED that any motion of any party in this action requesting to stay this case pending resolution of any appeal of the Court's claim construction of the same claim term ("crystallized [binimetinib]") in the same patents (the Crystallized Binimetinib Patents) in the related Alembic/Sandoz litigation, Civil Action No. 22-1277-GBW, should be made by formal motion or agreed to by stipulation and [proposed order] of the parties filed in this action on or before November 8, 2024. ORDERED by Judge Gregory B. Williams on 10/22/2024. (lnb) (Entered: 10/22/2024) (0) |
| Oct 17, 2024 | 15 | Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding Plaintiff's Proposed Scheduling Order - re 13 Order,,,. (Attachments: # 1 Text of Proposed Order)(Dellinger, Megan) (Entered: 10/17/2024) (0) |
| Oct 3, 2024 | 14 | STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order to October 17, 2024 - filed by Array BioPharma Inc.. (Dellinger, Megan) (Entered: 10/03/2024) (2) |
| Sep 3, 2024 | 13 | ORAL ORDER: IT IS HEREBY ORDERED that, not later than thirty (30) days from the date of this Order, the parties shall meet and confer and file a joint proposed Scheduling Order in this action consistent with the applicable form Scheduling Order of Judge Williams, which is posted at http://www/ded/uscourts.gov (See Chambers, Judge Williams, Forms), along with a cover letter requesting the Court to enter the joint proposed Scheduling Order (if there are no disputes or other issues concerning scheduling that the Court needs to address) or to schedule the Rule 16 Scheduling Conference. If there are disputes or other issues the Court needs to address in the joint proposed Scheduling Order, in the cover letter, the parties shall direct the Court to the paragraph numbers in the joint proposed Scheduling Order which those appear. ORDERED by Judge Gregory B. Williams on 9/3/24. (jaa) (Entered: 09/03/2024) (0) |
| Aug 24, 2023 | 12 | ANSWER to 10 Answer to Complaint, Counterclaim by Array BioPharma Inc..(Dellinger, Megan) (Entered: 08/24/2023) (8) |
| Aug 4, 2023 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Daryl L. Wiesen, Alexandra D. Valenti, Gabriel Ferrante, and Christopher J. Cassella - filed by Teva Pharmaceuticals, Inc.. (Russell, Andrew) (Entered: 08/04/2023) (7) |
| Aug 4, 2023 | 10 | ANSWER to 1 Complaint Affirmative Defenses, COUNTERCLAIM against Array BioPharma Inc. by Teva Pharmaceuticals, Inc..(Russell, Andrew) (Entered: 08/04/2023) (26) |
| Aug 4, 2023 | 11 | Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals, Inc.. (Russell, Andrew) (Entered: 08/04/2023) (2) |
| Jun 26, 2023 | N/A | SO ORDERED, re 8 STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to August 4, 2023 filed by Teva Pharmaceuticals, Inc. Signed by Judge Gregory B. Williams on 6/26/2023. (etg) (Entered: 06/26/2023) (0) |
| Jun 22, 2023 | 8 | STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint to August 4, 2023 - filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) (Entered: 06/22/2023) (1) |
| Jun 14, 2023 | 7 | SUMMONS Returned Executed by Array BioPharma Inc..Teva Pharmaceuticals, Inc. served on 6/14/2023, answer due 7/5/2023. (Dellinger, Megan) (Entered: 06/14/2023) (2) |
| Jun 14, 2023 | N/A | Case Assigned to Judge Gregory B. Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (rjb) (Entered: 06/14/2023) (0) |
| Jun 8, 2023 | 1 | COMPLAINT filed against Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4154119.) - filed by Array BioPharma Inc. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(smg) (Entered: 06/08/2023) (Main Document) (11) |
| Jun 8, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (smg) (Entered: 06/08/2023) (3) |
| Jun 8, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/09/2022. Date of Expiration of Patent: 10/18/2033. (smg) (Entered: 06/08/2023) (1) |
| Jun 8, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,562,016 B2; 9,598,376 B2; 9,980,944 B2. (smg) (Entered: 06/08/2023) (1) |
| Jun 8, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Pfizer Inc. for Array BioPharma Inc. filed by Array BioPharma Inc. (smg) (Entered: 06/08/2023) (1) |
| Jun 8, 2023 | 6 | Summonses Issued (please complete the top portion of the form and print out for use/service). (smg) (Entered: 06/08/2023) (2) |
| Jun 8, 2023 | 1 | COMPLAINT filed against Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4154119.) - filed by Array BioPharma Inc. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(smg) (Entered: 06/08/2023) (Exhibit A) (30) |
| Jun 8, 2023 | 1 | COMPLAINT filed against Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4154119.) - filed by Array BioPharma Inc. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(smg) (Entered: 06/08/2023) (Civil Cover Sheet) (1) |
